Role of isocitrate dehydrogenase 1/2 (IDH 1/2) gene mutations in human tumors

被引：1
作者：
Liu, Xiang [1 ]
Ling, Zhi-Qiang [1 ]
机构：
[1] Zhejiang Prov Canc Hosp, Zhejiang Canc Ctr, Zhejiang Canc Res Inst, Hangzhou 310022, Zhejiang, Peoples R China
来源：
HISTOLOGY AND HISTOPATHOLOGY | 2015年 / 30卷 / 10期
关键词：
Isocitrate dehydrogenase 1/2 (IDH1/IDH2); Mutation; Methylation; Metabolism; Tumorigenesis; IDH2; MUTATIONS; ONCOMETABOLITE; 2-HYDROXYGLUTARATE; INHIBITOR;
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
In recent years, frequent isocitrate dehydrogenase 1/2 (IDH1/IDH2) gene mutations were found in a variety of tumors, which specifically alter arginine residues of catalytic active site in IDH1/IDH2 and confer new enzymatic function of directly catalyzing alpha-ketoglutarate (alpha-KG) to R-2-hydroxyglutarate (2HG). 2-HG could competitively inhibit alpha-KG-dependent enzymes and might therefore contribute to tumorigenesis. In addition, mutation status of IDH1/IDH2 is closely related to the progress and prognosis of certain tumors. Thus IDH1/IDH2 is considered to be a promising biomarker for early diagnosis and prognosis and targeted therapy. In this study, the current research on IDH1/IDH2 mutation, especially the mechanisms and clinical characteristics related to tumor, are reviewed.
引用
收藏
页码：1155 / 1160
页数：6
相关论文
共 29 条
  • [1] [Anonymous], 2014, ABSTR APPL AN
  • [2] IDH1 R132H Decreases Proliferation of Glioma Cell Lines In Vitro and In Vivo
    Bralten, Linda B. C.
    Kloosterhof, Nanne K.
    Balvers, Rutger
    Sacchetti, Andrea
    Lapre, Lariesa
    Lamfers, Martine
    Leenstra, Sieger
    de Jonge, Hugo
    Kros, Johan M.
    Jansen, Erwin E. W.
    Struys, Eduard A.
    Jakobs, Cornelis
    Salomons, Gajja S.
    Diks, Sander H.
    Peppelenbosch, Maikel
    Kremer, Andreas
    Hoogenraad, Casper C.
    Smitt, Peter A. E. Sillevis
    French, Pim J.
    [J]. ANNALS OF NEUROLOGY, 2011, 69 (03) : 455 - 463
  • [3] The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
    Chowdhury, Rasheduzzaman
    Yeoh, Kar Kheng
    Tian, Ya-Min
    Hillringhaus, Lars
    Bagg, Eleanor A.
    Rose, Nathan R.
    Leung, Ivanhoe K. H.
    Li, Xuan S.
    Woon, Esther C. Y.
    Yang, Ming
    McDonough, Michael A.
    King, Oliver N.
    Clifton, Ian J.
    Klose, Robert J.
    Claridge, Timothy D. W.
    Ratcliffe, Peter J.
    Schofield, Christopher J.
    Kawamura, Akane
    [J]. EMBO REPORTS, 2011, 12 (05) : 463 - 469
  • [4] Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (vol 462, pg 739, 2010)
    Dang, Lenny
    White, David W.
    Gross, Stefan
    Bennett, Bryson D.
    Bittinger, Mark A.
    Driggers, Edward M.
    Fantin, Valeria R.
    Jang, Hyun Gyung
    Jin, Shengfang
    Keenan, Marie C.
    Marks, Kevin M.
    Prins, Robert M.
    Ward, Patrick S.
    Yen, Katharine E.
    Liau, Linda M.
    Rabinowitz, Joshua D.
    Cantley, Lewis C.
    Thompson, Craig B.
    Vander Heiden, Matthew G.
    Su, Shinsan M.
    [J]. NATURE, 2010, 465 (7300) : 966 - 966
  • [5] Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
    Figueroa, Maria E.
    Abdel-Wahab, Omar
    Lu, Chao
    Ward, Patrick S.
    Patel, Jay
    Shih, Alan
    Li, Yushan
    Bhagwat, Neha
    Vasanthakumar, Aparna
    Fernandez, Hugo F.
    Tallman, Martin S.
    Sun, Zhuoxin
    Wolniak, Kristy
    Peeters, Justine K.
    Liu, Wei
    Choe, Sung E.
    Fantin, Valeria R.
    Paietta, Elisabeth
    Lowenberg, Bob
    Licht, Jonathan D.
    Godley, Lucy A.
    Delwel, Ruud
    Valk, Peter J. M.
    Thompson, Craig B.
    Levine, Ross L.
    Melnick, An
    [J]. CANCER CELL, 2010, 18 (06) : 553 - 567
  • [6] HIF-1α downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation
    He, M.
    Wang, Q-Y
    Yin, Q-Q
    Tang, J.
    Lu, Y.
    Zhou, C-X
    Duan, C-W
    Hong, D-L
    Tanaka, T.
    Chen, G-Q
    Zhao, Q.
    [J]. CELL DEATH AND DIFFERENTIATION, 2013, 20 (03) : 408 - 418
  • [7] IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
    Houillier, C.
    Wang, X.
    Kaloshi, G.
    Mokhtari, K.
    Guillevin, R.
    Laffaire, J.
    Paris, S.
    Boisselier, B.
    Idbaih, A.
    Laigle-Donadey, F.
    Hoang-Xuan, K.
    Sanson, M.
    Delattre, J. -Y.
    [J]. NEUROLOGY, 2010, 75 (17) : 1560 - 1566
  • [8] IDH Mutations in Human Glioma
    Kim, Won
    Liau, Linda M.
    [J]. NEUROSURGERY CLINICS OF NORTH AMERICA, 2012, 23 (03) : 471 - +
  • [9] Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
    Koivunen, Peppi
    Lee, Sungwoo
    Duncan, Christopher G.
    Lopez, Giselle
    Lu, Gang
    Ramkissoon, Shakti
    Losman, Julie A.
    Joensuu, Paivi
    Bergmann, Ulrich
    Gross, Stefan
    Travins, Jeremy
    Weiss, Samuel
    Looper, Ryan
    Ligon, Keith L.
    Verhaak, Roel G. W.
    Yan, Hai
    Kaelin, William G., Jr.
    [J]. NATURE, 2012, 483 (7390) : 485 - U144
  • [10] Molecular mechanisms and potential functions of histone demethylases
    Kooistra, Susanne Marije
    Helin, Kristian
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2012, 13 (05) : 297 - 311
123